Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Puma Biotechnology, Inc.NASDAQ: PBYI

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 76.7%

Gross margin was 76.7% in Q1 FY2026, down 0.3 pp from a year earlier. On a trailing-twelve-month basis it was 74.5%, up 2.1 pp year over year. Over 3 fiscal years it narrowed by 1.3 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
76.7%+7.4 pp QoQ
Last fiscal yearDec 2025
74.5%+2.5 pp YoY
LTMMar 2026
74.5%+2.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.3 pp——
1 year+2.5 pp——
3 years-1.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
74.5%
Year-over-year change
+2.5pp

Gross Margin vs competitors

How PBYI compares with its peers on the latest reported figures

  • PBYI's LTM Mar 2026 gross margin of 74.5% is the 5th highest of the 7 companies compared; the peer median is 88.8%.
  • Its year-over-year change of +2.1 pp is the 3rd highest of 6, against a peer median of -3.7 pp.
  • Over three fiscal years its change of -1.3 pp compares with a peer median of -10.4 pp.
PBYI Competitors Peer median
Gross Margin for PBYI and competitors
Company Period LTM level YoY 3-year change
BDTXBlack Diamond Therapeutics, Inc.FY202599.5% ——
TNGXTango Therapeutics, Inc.FY202596.3% -3.7 pp-3.7 pp
NUVBNuvation Bio Inc.LTM Jun 202693.9% +66.4 pp—
VSTMVerastem, Inc.LTM Mar 202683.7% -16.3 pp-17.1 pp
PBYIPuma Biotechnology, Inc.LTM Mar 202674.5% +2.1 pp-1.3 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-2105.7% -548.4 pp+0.0 pp
ORICORIC Pharmaceuticals, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
NBPNovaBridge BiosciencesFY2025— ——
ONCYOncolytics Biotech Inc.FY2025— ——
Peer median (excluding PBYI) 88.8%-3.7 pp-10.4 pp

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue253.16M228.03M235.64M230.47M228.37M
Cost of Revenue63.7M55.09M62.68M64.4M58.16M
Gross Profit189.45M172.94M172.96M166.06M170.21M
Gross Margin74.8%75.8%73.4%72.1%74.5%
Research & Development71.87M52.24M50.38M54.94M62.07M
Selling, General & Admin116.29M89.98M89.31M80.16M71.21M
Operating Expenses188.16M149.22M140.32M135.1M132.92M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
EBITDA(4.69M)21.89M47.52M48.08M53.34M
EBITDA Margin-1.9%9.6%20.2%20.9%23.4%
Operating Income1.29M23.72M32.64M30.97M37.3M
Operating Margin0.5%10.4%13.9%13.4%16.3%
Interest Income160K813K2.61M4.72M4.08M
Interest Expense12.81M11.59M13.33M12.45M6.62M
Other Income / Expenses(30.09M)(23.26M)(9.97M)(6.87M)(1.52M)
Income Before Tax(28.8M)457K22.67M24.1M35.78M
Pre-Tax Margin-11.4%0.2%9.6%10.5%15.7%
Income Tax Expense324K455K1.08M(6.18M)4.67M
Net Income(29.13M)2K21.59M30.28M31.11M
Net Margin-11.5%0.0%9.2%13.1%13.6%
EPS (Basic)(0.72)0.020.460.620.62
EPS (Diluted)(0.72)0.020.450.620.61
Weighted Avg Shares40.64M44.67M47.13M48.65M50.01M
Weighted Avg Shares (Diluted)40.64M44.93M47.55M49.1M50.65M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.